Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Completed 18Recruiting 17Active not recruiting 11Terminated 10Unknown 4Not yet recruiting 3Withdrawn 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Lymphoid 3Other solid neoplasm 1Gastrointestinal 1

Conditions

Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cytarabine 102Cyclophosphamide 74fludarabine 45Idarubicin 39Decitabine 36Etoposide 35Azacitidine 34Methotrexate 31Daunorubicin 30Vincristine 28Dexamethasone 27venetoclax 25Busulfan 24Imatinib Mesylate 23Radiotherapy 20Mercaptopurine 20Granulocyte Colony-Stimulating Factor 20Dasatinib 19Peripheral Blood Stem Cell Transplantation 18Mitoxantrone 17Doxorubicin 17Immunotherapy, Adoptive 16Rituximab 15Asparaginase 15Tretinoin 14Cladribine 14fludarabine phosphate 13Prednisone 13Prednisolone 13Melphalan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × ruxolitinib × Other hematologic neoplasm × Clear all
NCT05413356 2022-10-19

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
50 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT03558607 2020-03-19

The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

Seoul National University Hospital

Phase 1/2 Unknown
17 enrolled
MyeloidOther hematologic neoplasm

Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder

NCT03613428 2018-08-03

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Sichuan University

Phase 1/2 Unknown
12 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02912754 2017-03-13

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Sunnybrook Health Sciences Centre

Phase 1/2 Unknown
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡